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Background: In theory, cerebral biopsies could provide the diagnosis in a significant proportion of patients with
neurodegenerative diseases, however, there are considerable ethical barriers. Previous series of cerebral biopsies have
shown variable diagnostic accuracy but have understandably suffered because of lack of post-mortem tissue with
which to compare the diagnosis. To determine the accuracy of such biopsies in neurodegenerative disease we took
small biopsy-sized samples of predominantly fresh post-mortem brain tissue from frontal and temporal lobes in 62
cases. These were processed as for a biopsy and stained for H&E, p62, tau, Aβ, α-synuclein, and TDP-43. The sections
were assessed blind by 3 neuropathologists and the results compared with the final post-mortem diagnosis.
Results: The agreement and sensitivity in most cases was good especially: controls; Alzheimer’s disease (AD); multiple
system atrophy (MSA); frontotemporal lobar degeneration with TDP-43 positive inclusions and/or motor neurone
disease (FTLD-TDP/MND); Huntington’s disease (HD); corticobasal degeneration (CBD) / microtubular associated protein
tau mutation cases with CBD-like features (CBD/MAPT); and combined AD- Dementia with Lewy Bodies (AD-DLB)
where the sensitivity on assessing both brain regions varied between 75-100%. There was poor sensitivity for
progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis (ALS) (both 0%), but moderate sensitivity for pure
DLB (60%). The temporal lobe assessment was marginally more accurate than the frontal lobe but these were only
slightly worse than both combined.
Conclusions: The study shows that with certain caveats the cerebral biopsy in life should be a viable method of
accurately diagnosing many neurodegenerative diseases.
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Despite significant advances in neuroradiological tech-
niques and the emergence of possible biomarkers [1,2] the
gold standard for diagnosis of neurodegenerative diseases
remains the histological examination of post mortem
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reproduction in any medium, provided the ornew targeted therapies emerge the accurate diagnosis of
neurodegenerative diseases in life may well become even
more important. In theory, definitive diagnosis of several
neurodegenerative diseases in life can be made on a surgi-
cally removed brain biopsy. There are, however, inherent
risks associated with brain biopsies including seizures,
bleeding and infection [3-5]. Whilst these risks are often
deemed acceptable when attempting to diagnose poten-
tially treatable severe conditions such as brain tumours,
ethically there is much greater difficulty in justifying
biopsies in non-tumour conditions where few treatment
options exist. For this reason brain biopsies for potentiald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cases where there has been a need to rule out some other
possible treatable conditions such as infection or vascu-
litis. Because of this, such biopsies have tended to be done
in younger to middle-aged patients rather than in those
more prone to neurodegenerative disease [5]. There have
been relatively few studies of the efficacy of brain biopsy
in non-tumour conditions, especially those concentrating
on the diagnosis of neurodegenerative disease [3-8]. By ne-
cessity the correct diagnosis in the majority of cases had
to be evaluated by retrospective analysis of clinical features
and scans with only a minority being able to be compared
with a later post-mortem examination of the brain [5]. Be-
cause of these limitations up to 37% of the biopsies were
considered non diagnostic, often the only features being
non specific gliosis [5,7]. Venneti et al., however, using a
simulated brain biopsy technique on partially-covered
post-mortem brain slides attempted to determine the ac-
curacy of biopsy interpretation by comparing the results
with the final autopsy diagnosis [9]. They achieved rela-
tively good sensitivity for many diseases when assessing
frontal lobe only, but when 4 brain regions were assessed
the accuracy increased considerably. However, they con-
ceded that at least one of the four regions (basal ganglia)
would probably not be appropriate for a routine biopsy
procedure, and the analysis suffered a little on being retro-
spective in nature. The aim of this current study was
therefore again to assess the accuracy of a simulated brain
biopsy, but on this occasion by using fresh post-mortem
brain tissue. The technique would allow sampling of the
same potential biopsy sites as those targeted in life by
neurosurgeons, whilst at the same time allowing good
comparison with the final neuropathological diagnosis on
the whole fixed brain.
Methods
Formalin fixed paraffin embedded tissue from a total of 62
cases were obtained from the Medical Research Council
(MRC) London Neurodegenerative Diseases Brain Bank,
Institute of Psychiatry, King’s College London, London,
UK. All subjects gave informed consent for tissue
donation using procedures approved by the local Research
Ethics Committee.
Following our neurosurgeon’s (KA) instruction, biopsy
like samples of 1 cm3 cortical brain tissue from dorsolat-
eral/anterior prefrontal (Brodmann area 9/10) and middle
temporal cortex (Brodmann area 21) were dissected from
46 consecutive brain bank cases received between October
2011 and May 2012. The protocol for the MRC Brain
Bank involves bisecting the brain prior to fixing one half
and slicing and freezing the other, and the biopsy samples
were taken from the half to be fixed. The tissue blocks
were immediately fixed in 10% buffered formalin for one
week and processed into paraffin blocks. In order toprovide a greater balance and range of neurodegenerative
diseases, one of the authors (CT) who was not involved in
the histological assessment used fixed archival brains and
provided biopsy sized samples from the same brain re-
gions from 16 confirmed diagnoses of different neuro-
logical diseases and controls. These details remained blind
to the histological evaluators.
The fixation times for those 16 cases ranged from 2-
132 months. Those cases that were added in this fashion
were Dementia with Lewy Bodies neocortical/limbic
stages (DLB) [10] -2 cases; Corticobasal degeneration
(CBD) or microtubular associated protein tau (MAPT)
mutation-with CBD features (CBD/MAPT)-4 cases
(because even after post-mortem evaluation of the brain,
the cases of MAPT mutations seen here were indistin-
guishable from CBD and without genetic analysis it was
considered that for this particular study they should
be considered as one group); Multiple system atrophy
(MSA) -2 cases; Progressive supranuclear palsy (PSP)-2
cases; Pure Alzheimer’s Disease (AD) (Modified Braak/
Brain Net Europe (BNE) Stage IV-VI) [11] -2 cases;
Huntington’s Disease (HD)- 2 cases; Controls (no history
of cognitive decline or movement disorder, maximum
modified Braak (BNE) AD stage of II) [11] - 2 cases.
The autopsy confirmed cases therefore overall were as
follows:
Controls - 9 cases; pure AD (Modified Braak (BNE)
Stage IV-VI [11] - 15 cases; PSP -3 cases; CBD/MAPT-
7 cases; neocortical/limbic stages of DLB [10] - 5 cases;
MSA - 3 cases; HD-6 cases; frontotemporal lobar degen-
eration with TDP-43 positive inclusions with or without
motor neurone disease (FTLD-TDP/FTLD-MND)-6
cases; metabolic diseases (Batten’s Disease)-1 case; pure
cerebrovascular disease -1 case; Combined AD (Modi-
fied Braak (BNE) Stage IV-VI) [11] and DLB (neocor-
tical/limbic stage) [10] - 4 cases; Amyotrophic Lateral
Sclerosis (ALS) (no extramotor inclusions) - 2 cases.
The details of the cases are illustrated in Table 1.
Because of the relevant strict Health and Safety proce-
dures in dealing with fresh tissue it was not considered
possible to use prion disease cases in the evaluation [12].
All the blocks were cut at 7 μm thickness and stained
with haematoxylin and eosin (H&E). Sections were also
immunohistochemically stained with the mouse monoclo-
nal antibody to p62 (1:100; BD Biosciences, Erembodegem,
Belgium), phosphorylated tau (clone [AT-8]; 1:500;
Autogen Bioclear UK Ltd, Wiltshire, UK), α-synuclein
(clone [42/α synuclein]; 1:500; Novocastra Laboratories
Ltd, Newcastle-upon-Tyne, UK), and Amyloid β (Aβ)
(1:12000; Chemicon, Temecula, CA, USA), or the rabbit
polyclonal antibody to phosphorylated TDP-43 (pS409/
410-2; 1:1500); Cosmo Bio Ltd, Tokyo, Japan) using the
Leica BONDMAX™ (Leica Biosystems, Wetzlar, Germany).
Leica BONDMAX™ epitope retrieval sets was used for
Table 1 Showing the number and range of cases from which simulated brain biopsies were taken
Cases Number in group Relevant stages Comments
Control 9 AD (BNE/Braak) 0-II [11]
AD 15 AD (BNE/Braak) IV-VI 2 cases mild cortical TDP-43
PSP 3
CBD 5 Total = 7
MAPT (with CBD pathology) 2




FTLD-TDP/FTLD-MND 6 FTLD-TDP -1 1 case C9orf72 mutation
FTLD-MND -5
Metabolic disease 1 Batten’s disease CLN2 mutation
Cerebrovascular disease 1 Infarct and amyloid angiopathy
ALS 2 No extramotor inclusions
Combined AD and DLB 4 AD (BNE Braak) (V-VI) 1 case mild cortical TDP-43
DLB Limbic -2
DLB Neocortical - 2
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and tau (ER1 for 20 minutes). For both α synuclein, and
Aβ 80% formic acid pre-treatment (for 1 hour) was used.
Nuclei were counterstained with Harris’ alum hema-
toxylin. All cases were examined independently by the
three neuropathologists (SAS, AK, IB) blind to clinical in-
formation, final post-mortem diagnoses and overall range
of final diagnoses. All immunostained sections were semi-
quantitatively rated as having no (-), only very occasional
(+/-), mild (+), moderate (++) or severe (+++) immunore-
activity. The frontal and temporal lobe biopsies were
assessed both separately and combined by each assessor
and then a diagnosis attempted on each block separately
and then both combined. Briefly the characteristic histo-
logical features searched for were tau positive neuritic
plaques, neuropil threads and neurofibrillary tangles and
Aβ positive plaques in AD; α-synuclein and p62 positive
Lewy bodies and Lewy Neurites in DLB; α-synuclein and
p62 positive oligodendroglial cell inclusions in MSA;
TDP-43 and p62 positive inclusions in FTLD-TDP/MND
(and ALS) [13]; tau positive globose tangles and tufted
astroctyes in PSP; tau positive, p62 positive astrocytic
plaques and possible balloon cells in CBD/MAPT; Pick
bodies in Pick’s Disease (PiD); p62 positive, TDP-43 nega-
tive neuronal intranuclear inclusions (NII) in HD; infarc-
tion, or severe ischaemic changes with vascular wall
changes including possible amyloid angiopathy for cere-
brovascular disease. An adapted associated algorithm for
the diagnostic approach is shown in Figure 1 [7,9,14,15].
The final gold standard autopsy diagnoses were made
using the consensus criteria available for DLB [10], andthe BNE staging for AD [11]. In other cases agreement
was reached by the 3 pathologists after examining the
autopsy slides, with access to relevant clinical and genetic
details but totally blind to the results of the biopsy
assessments.
Statistical evaluation of the 62 cases (against the 12 cat-
egories of disease stated above) was made using an online
statistical package (www.statstodo.com). Statistical signifi-
cance was set at the 0.05 level. Agreement between the
frontal and temporal lobe assessments (both separately
and combined) and the gold standard autopsy diagnosis
was assessed with the kappa coefficient. Point estimates
and 95% confidence intervals (CI) were obtained for the
kappa coefficient. Kappa values were interpreted using
proposals of Landis and Koch [16]; kappa values below 0
indicate “poor” agreement, 0-0.20 “slight” agreement,
0.21-0.40 “fair” agreement, 0.41-0.60 “moderate” agree-
ment, 0.61-0.80 “substantial” agreement, and 0.81-1.00
“almost perfect” agreement. Within each group overall
sensitivity was calculated as the probability of a positive
test given that the patient had the disease, and the specifi-
city overall as the probability of a negative test given that
the patient did not have the disease. For this purpose all 3
raters had to be in agreement with the particular final
diagnosis to indicate a positive test.
Results
The overall results of the assessments are summarised in
Table 2. In addition, the histological features for a range
of the neurodegenerative diseases diagnosed are illus-
trated in Figure 2.
Figure 1 Suggested diagnostic algorithm for cerebral biopsies in the diagnosis of neurodegenerative diseases based on the simulated
biopsy technique. The broken lines and italics indicates groups of diseases which were not actually assessed in this study.
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standard autopsy diagnosis (frontal lobe alone kappa =
0.84, 95% CI = 0.80 - 0.88, p<0.001, temporal lobe alone
kappa = 0.86, 95% CI= 0.82 - 0.90, p<0.001 combined
kappa = 0.87, 95% CI= 0.83 - 0.91, p<0.001). Therefore
assessing the temporal lobe alone was marginally more ac-
curate than assessing the frontal lobe alone but both yieldedexcellent results and this accuracy increased only slightly
when combining the assessment of both biopsy sites.
The overall sensitivity for combined sites was 85%,
compared to 81% for the frontal lobe alone, and 84% for
the temporal lobe alone. The overall specificity for com-
bined sites was 83% compared to 79% for the frontal
lobe alone, and 82% for the temporal lobe alone.
Table 2 Illustrating the diagnostic accuracy of the assessors for particular disease groups when examining the
simulated biopsies from the frontal lobe, the temporal lobe and combined
Cases No. Correct diagnosis Comments
C-combined, F-Frontal, T-Temporal
Control 9 C-9 (100%), F-100%, T-100%
AD 15 C-15 (100%), F-100%, T-100%
PSP 3 C-0 (0%), F-0%, T-0% 1 assessor detected*
CBD/MAPT 7 C- 7 (100%), F-100%, T-100%
DLB 5 C- 3 (60%), F-60%, T-40%
MSA 3 C- 3 (100%), F-100%, T-100%
HD 6 C- 5 (83%), F-83%, T-83% 1 assessor missed†
FTLD-TDP/FTLD-MND 6 C- 5 (83%), F-67%, T-83% 1-2 assessor(s) missed #
Metabolic disease 1 C-1 (100%), F-100%, T-100%
Cerebrovascular disease 1 C-1 (100%), F-100%, T-100%
ALS 2 C- 0 (0%), F-0%, T-0%
Combined AD and DLB 4 C-3 (75%), F-75%, T-75% 1 assessor missed in limbic DLB case~
*- 1 assessor diagnosed PSP in one case only.
†- 1 assessor missed diagnosis in one case.
# - 1 assessor missed diagnosis in one case, 1 assessor missed another diagnosis in another case when examining frontal lobe.
~ - 1 assessor missed diagnosis in one combined AD-DLB case when DLB component was of limbic stage.
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ment with each other but nonetheless were unable to
diagnose the correct disease. For example in 2 of the 3
cases of PSP all the assessors diagnosed “controls” (the
other case of PSP was only detected by 1 assessor) (0%
sensitivity). Again in both the ALS cases (0% sensitivity) as
well as 2 of the 5 DLB (60% sensitivity) cases there was
consensus between the assessors but with an an incorrect
diagnosis. In contrast, on the combined assessment there
was complete agreement (100% sensitivity) for the cases of
pure AD, CBD/MAPT, MSA, cerebrovascular disease,
metabolic disease, and controls. There was a single rater
discrepancy in only 1 of the 6 cases of FTLD-TDP/MND
(83% sensitivity), 1 of the 6 cases of HD (83% sensitivity)
and 1 of the 4 cases of combined AD-DLB (75% sensitiv-
ity). In addition, occasional incidental TDP-43 inclusions
were noted by all raters in 2 of the cases of AD and 1 case
of combined AD-DLB. The temporal lobe biopsy (83%
sensitivity) appeared slightly better at detecting TDP-43
inclusions in cases of FTLD-TDP/MND than the frontal
lobe biopsy (67% sensitivity) but the frontal lobe biopsy
(60% sensitivity) detected Lewy Bodies in one case of DLB,
which was not present on the temporal lobe biopsy (40%
sensitivity). In many cases of AD the tau pathology was
more abundant in the temporal lobe biopsy than the
frontal lobe biopsy, but this did not appear to affect the
final diagnosis either when the biopsies were analysed sep-
arately or together. Because of excess p62 pathology one
rater correctly suggested a c9orf72 repeat expansion in
one case of FTLD-MND [17,18]. The suggested limita-
tions and usefulness of the biopsy technique depicted here
is illustrated in Table 3.Discussion
The potential risks of surgical biopsy are not insignifi-
cant with an estimated complication rate of usually be-
tween 5-11% but occasionally reaching 21%. These
complications include haemorrhage, neurological deficit,
infection, anaesthetic complications, eplilepsy and death
[3-5,7]. Thus for tumours where treatment options are
available biopsies are commonly performed. When con-
sidering such biopsies for non-tumour conditions there
is obviously an ethical dimension to take into account.
For this reason such biopsies have tended to be confined
to potentially treatable conditions such as suspected vas-
culitis or infection rather than dementias. They have also
tended to be performed in younger patients than those
commonly affected with neurodegenerative diseases [7].
Nevertheless, biopsies in suspected neurodegenerative
diseases have occasionally been performed in an attempt
to rule out an alternative treatable cause of the cognitive
decline or movement disorder [3-8,19]. Whilst some cli-
nicians consider the procedure in this context a neces-
sary evil even if it only provides information to a
patient’s relatives, and allows the cessation of non neces-
sary treatment, others consider it to be highly dubious
ethically, of little therapeutic use and indeed they have
raised concerns over obtaining informed consent for the
procedure [3,20,21]. If particular disease specific therap-
ies emerge prior to the validation of associated disease
biomarkers the use of cerebral biopsies may become an
important tool in the diagnosis of neurodegenerative dis-
eases in life. So far there is little evidence as to the ac-
curacy of the procedure in such diseases. Those studies
that have occurred have been mainly biopsy series with
Figure 2 Histological features from simulated biopsies of neurodegenerative diseases diagnosed in the study. (a) Alzheimer’s disease
illustrating the high density of tau positive neuropil threads, neuritic plaques and a neurofibrillary tangle (inset) (anti-tau). (b) Alzheimer’s disease
revealing Aβ positive plaques in the cortex and evidence of amyloid angiopathy (anti-Aβ). (c) Multiple system atrophy (MSA) showing numerous
p62 positive and α-synuclein positive (inset) oligodendroglial cytoplasmic inclusions in cerebral white matter. (d) Corticobasal degeneration
showing a tau positive astrocytic plaque in the cortex (anti-tau). (e) Huntington’s disease revealing p62 positive intranuclear inclusions within
neurones (anti-p62). (f) Frontotemporal lobar degeneration with TDP-43 positive inclusions (FTLD-TDP) showing TDP-43 positive neuronal
cytoplasmic inclusions in the neocortex (anti-TDP-43). (g) Dementia with Lewy bodies illustrating α-synuclein positive Lewy bodies in the
neocortex and a Lewy body at higher magnification (inset) (anti-α-synuclein). (h) Batten’s disease (neuronal ceroid lipfuscinosis type 2) showing
enlarged neurones with excess granular cytoplasmic material (H&E). Main pictures (a), (b) show ×20 magnifications; (c), (d) (g) show ×40
magnifications, (f) (h) and inset for (a) show ×60 magnifications. (e) and inset for (c) show ×120 magnifications and inset for (g) shows ×
100 magnification.
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accuracy in diagnoses in such series has necessarily in-
volved retrospective analysis of scans, clinical parameters
and subsequent disease course and (including all non-tumour conditions, not just neurodegenerative diseases)
has varied between 53% and 77% [4-8,19]. There were a
number of cases which gave a non specific diagnosis. It
was interesting that the follow up study at one centre






















AD (IV-VI) High F or T HE, tau, p62, Aβ TDP-43, α-syn History, scans



















MAPT mutation Likely to depend
on mutation











F >T HE, p62, α-syn, Aβ, tau, TDP-43 History, scans Often seen with AD
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MSA High F or T HE, p62, α-syn, tau History, scans White matter essential
in the biopsy
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PD Very low-nil N/A HE, p62 α-syn tau History, scans
genetics
Biopsy could rule out
other causes of
parkinsonism
Those cases in italics were not included in this study but features have been included and estimated from the following references [3,5,7,9]. AA amyloid
angiopathy, CVD cerebrovascular disease, CR congo red, F frontal lobe, FTD frontotemporal dementia, GFAP glial fibrillary acidic protein, LFB/N Luxol fast blue/
Nissl, N/A details not applicable, PAS Periodic acid Schiff, PiD Pick’s disease, PD Parkinson’s disease, PrP prion protein, α-syn α-synuclein, T temporal lobe.
> - estimated to be more slightly more sensitive site than.
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over a 5 year period, perhaps reflecting greater range of
specific antibodies available and greater experience on
the part of the pathologists [5,7]. However, it was also
noted that the number of biopsies had decreased per-
haps with the physicians concentrating on those most
likely to give a definitive answer. Venneti et al. mindful
of needing to provide a definitive answer when assessingthe accuracy of cerebral biopsies in neurodegenerative
diseases used partially covered post-mortem slides to
simulate brain biopsies [9]. They achieved a very good
sensitivity and inter-rater reliability for most cases,
when assessing 4 brain regions and these remained high
when examining frontal lobe only. The authors con-
ceded that one of the regions (basal ganglia) would be
less likely biopsied in life, also that there were some
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such as this. Our study tried as much as possible to
simulate a cerebral biopsy in life by taking small samples
from the frontal and temporal regions and in most cases
fixing and processing as one would a biopsy rather than
autopsy blocks.
By using this simulated brain biopsy technique we ex-
amined 62 cases and compared the assessments with the
final post-mortem diagnosis. With the majority of neu-
rodegenerative diseases assessed we managed high ac-
curacy using either the frontal or temporal lobe or both
together. The pathologists were particularly accurate at
detecting pure AD, CBD/MAPT, MSA, combined AD-
DLB, FTLD-TDP/MND, HD, cerebrovascular disease,
metabolic disease, and controls. They were, however,
poor at detecting PSP and this agrees with the findings
of Venneti et al. and probably reflects the relative pau-
city of tau expression in the neocortex and white matter
when compared with brain stem, basal ganglia and cere-
bellar pathology [9]. Since 2 of the 3 cases of PSP were
from the archival tissue (fixation times of 5 years and
2 years respectively) there is a possibility that this
prolonged fixation time had deleterious effects on the
expression of the tau antibody. Dwork et al. however,
when assessing this phenomenon with the Alz-50 anti-
body (later seen to recognise a phosphorylated epitope
of tau) showed that whilst this effect does occur, it is not
often significant until 20 years have elapsed [22]. The as-
sessors were also relatively poor at assessing pure DLB,
but here the cases that were not detected were limbic
stage, (both alone or combined with AD) and on analysis
of the final post-mortem brain the α-synuclein pathology
was not indeed present in the location of the simulated
biopsy. Those cases missed by the assessors tended to be
in the limbic stage according to the McKeith classifica-
tion, in that at autopsy they had only occasional Lewy
Bodies in the middle frontal and/or temporal neocortex
but not the parietal neocortex [10]. The 2 pure neocor-
tical stages of pure DLB were both diagnosed by all par-
ticipants from both biopsy regions and the 2 neocortical
stages of DLB when combined with AD were both also
recognised. Not surprisingly, none of the participants
could detect any pathology in the ALS cases since there
was no extramotor pathology seen in the autopsy brains.
What was particularly encouraging was the detection of
MSA cases even with relatively scanty white matter and
especially considering the fact that these cases were sub-
mitted from archival formalin wet tissue and α-synuclein
staining is somewhat susceptible to prolonged fixation
[23]. This would be a somewhat hypothetical problem
since in a live biopsy scenario prolonged fixation would
be unlikely. Furthermore, it was noted that the p62 was
a sensitive marker for detecting the characteristic “cup
and ball” oligodendroglial inclusions of MSA. Indeedp62 although non specific labels Lewy bodies, neurofib-
rillary tangles, glial inclusions of tauopathies and MSA,
inclusions in FTLD-TDP/MND as well as the intra-
nuclear inclusions of polyglutamine disorders such as
HD [24-26]. In this study therefore p62 proved to be in-
valuable as a primary “screening” stain. It was also inter-
esting to note that the staining protocol was sensitive
enough to detect secondary mild cortical TDP-43 path-
ology in 2 cases of pure AD and one case of mixed
AD-DLB. The significance of this TDP-43 pathology in
association with other diseases is somewhat obscure al-
though there is one study that does show such abnormal
TDP-43 expression may correlate with older age and dif-
ferent clinical features [27]. In the context seen here it
could theoretically modify any potential therapy or at
least give a clue as to the overall disease progression.
The detection of HD by p62 positive,TDP-43 negative
neuronal intranuclear staining again is an interesting yet
somewhat academic finding since aside from those pa-
tients with atypical clinical features the current availabil-
ity of a genetic test for HD would render such a biopsy
of little practical use.
One criticism that could be made of the study would
be that prion diseases were excluded. The main reason
for this is the Health and Safety aspects of dealing with
such cases (especially fresh brain tissue). The difficulty
in dealing with biopsies from prion disease cases has
already been more extensively studied [7]. In any case
the algorithm could be easily adapted to take into ac-
count of this particular possible diagnosis and as well as
performing immunohistochemistry fresh tissue could be
sent for analysis of the prion proten subtypes [28,29].
Again no PiD cases were present in our sample although
judging from the results here they would expected to
present little diagnostic difficulties on an adequately-sized
biopsy. Venneti et al. comfirmed a high rate of detection
in such cases [9]. Cases of frontotemporal lobar degener-
ation with fused in sarcoma (FUS) positive inclusions
(FTLD-FUS) are rare and were not seen in our series.
Potentially they could be important because they often
present in younger or middle-aged patients. This should
theoretically present little difficulty in that the neuronal
cytoplasmic inclusions should be p62 positive, and TDP-
43 negative and the addition of FUS immunohistochemis-
try to the repertoire should lead to the diagnosis [30,31].
When cerebral biopsies for non-tumour conditions are
taken they are usually from the non-dominant hemisphere
and in our cases it was considered more important to as-
sess the simulated biopsies from the same side as the fixed
cerebral hemisphere, and since the protocol for the MRC
brain bank requires alternating hemispheres for fixation
this could be seen as a potential deviation when compared
with in vivo biopsies. This however, would be unlikely to
represent a problem apart from the occasional cases of
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metry in degeneration and pathology (not seen in this
series). The vast majority of the specimens contained
leptomeninges by which to judge the presence and severity
of amyloid angiopathy, but there was seldom sufficient
white matter by which to judge diffuse white matter cere-
brovascular disease such as “Binswanger’s disease”.
The frontal lobe is the most widely biopsied site and
whilst the results here show slightly worse accuracy
when compared with the temporal lobe (either alone or
combined) it still appears to represent a sensitive area to
assess apart from in PSP and the limbic stages of DLB. It
should be remembered that these biopsies were assessed
blind to clinical and radiological details. Therefore, in a
real life situation where these additional assessments
and results would be available, the accuracy may well be
higher, and the diagnostic algorithm could be adjusted
such that those cases with either a high index of suspi-
cion for PSP or limbic DLB could either not be biopsied
at all (instead relying on other criteria) or else a negative
biopsy would not be taken to absolutely exclude the
diagnosis. Similarly, if FTLD-TDP/MND was in the dif-
ferential diagnosis there could be consideration as to
whether a temporal biopsy be taken so as to increase the
chance of a positive diagnosis. In addition, as illustrated
in Figure 1 the accuracy of the biopsy technique could
be further enhanced by the use of specific stains such
as 4-repeat and 3-repeat tau in the tauopathies and
polyglutamine antibodies in HD. The purpose of
attempting to establish biomarkers for various neurode-
generative disease is so that there can be detection of a
particular disease by a relatively non invasive technique
such that the prognosis can be attempted and hopefully
in the future therapeutic options can be considered [32].
Ideally the biomarker should detect the condition early
so that disease course can be prevented or at least
slowed down. One could argue that the simulated biopsy
technique seen here only allows detection of the estab-
lished (or end-stage) pathology and therefore is likely to
be of little practical use when possible therapies are be-
ing considered. It may indeed be that that the actual tak-
ing of the biopsy at the earlier stage could just reveal
non specific gliosis and this may explain the significant
proportion of such diagnoses seen in biopsy series
[5,7,8]. Even if this were the case, phase II studies in
clinical trials still involve testing therapies in established
disease groups and the brain biopsy technique may be
particularly useful in this situation.
Conclusions
Therefore we have shown in this study that with certain
caveats the simulated brain biopsy technique can accur-
ately detect the majority of neurodegenerative diseases.
The brain biopsy may become a useful diagnostic toolwhen considering treatment of these diseases with po-
tential targeted therapies.
Competing interest
The authors declare they have no competing interest.
Authors’ contributions
AK, SM, SAS, CT, IB, OC, KA designed the study. AK, IB, SAS made the
assessments. CT added additional cases. AK and SM drafted the manuscript.
All authors contributed to the manuscript and approved the final
manuscript.
Acknowledgements
We thank the donors and their families whose donation of brain and spinal
cord tissue to the Medical Research Council London Neurodegenerative
Diseases Brain Bank allowed this research to take place. We also thank the
staff of the Clinical Neuropathology Department, King’s College Hospital.
Author details
1Department of Clinical Neuropathology, Academic Neuroscience Building,
Kings College Hospital, SE5 9RS Denmark Hill, London, England. 2MRC
London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, King’s
College, London, UK. 3Department of Clinical Neuroscience, King’s Health
Partners Centre for Neurodegeneration Research, Institute of Psychiatry,
King’s College, London, UK. 4Department of Neurosurgery, King’s College
Hospital, London, UK.
Received: 12 August 2013 Accepted: 13 August 2013
Published: 19 August 2013
References
1. Hu WT, Chen-Plotkin A, Arnold SE, et al: Biomarker discovery for
Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's
disease. Acta Neuropathol 2010, 120:385–399.
2. Wu Y, Le W, Jankovic J: Preclinical biomarkers of Parkinson disease.
Arch Neurol 2011, 68:22–30.
3. Hulette CM, Earl NL, Crain BJ: Evaluation of cerebral biopsies for the
diagnosis of dementia. Arch Neurol 1992, 49:28–31.
4. Pulhorn H, Quigley DG, Bosma JJ, et al: Impact of brain biopsy on the
management of patients with nonneoplastic undiagnosed neurological
disorders. Neurosurgery 2008, 62:833–837.
5. Warren JD, Schott JM, Fox NC, et al: Brain biopsy in dementia. Brain 2005,
128:2016–2025.
6. Josephson SA, Papanastassiou AM, Berger MS, et al: The diagnostic utility
of brain biopsy procedures in patients with rapidly deteriorating
neurological conditions or dementia. J Neurosurg 2007, 106:72–75.
7. Schott JM, Reiniger L, Thom M, et al: Brain biopsy in dementia: clinical
indications and diagnostic approach. Acta Neuropathol 2010, 120:327–341.
8. Wong SH, Jenkinson MD, Faragher B, et al: Brain biopsy in the
management of neurology patients. Eur Neurol 2010, 64:42–45.
9. Venneti S, Robinson JL, Roy S, et al: Simulated brain biopsy for diagnosing
neurodegeneration using autopsy-confirmed cases. Acta Neuropathol
2011, 122:737–745.
10. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of
dementia with Lewy bodies: third report of the DLB consortium.
Neurology 2005, 65:1863–1872.
11. Alafuzoff I, Arzberger T, Al-Sarraj S, et al: Staging of neurofibrillary
pathology in Alzheimer's disease: a study of the BrainNet Europe
Consortium. Brain Pathol 2008, 18:484–496.
12. Ironside JW, Bell JE: The 'high-risk' neuropathological autopsy in AIDS and
Creutzfeldt-Jakob disease: principles and practice. Neuropathol Appl
Neurobiol 1996, 22:388–393.
13. Cairns NJ, Bigio EH, Mackenzie IR, et al: Neuropathologic diagnostic and
nosologic criteria for frontotemporal lobar degeneration: consensus of
the consortium for frontotemporal lobar degeneration. Acta Neuropathol
2007, 114:5–22.
14. Kleinschmidt-De Masters BK, Prayson RA: An algorithmic approach to the
brain biopsy--part I. Arch Pathol Lab Med 2006, 130:1630–1638.
15. Prayson RA, Kleinschmidt-DeMasters BK: An algorithmic approach to the
brain biopsy–part II. Arch Pathol Lab Med 2006, 130:1639–1648.
King et al. Acta Neuropathologica Communications 2013, 1:53 Page 10 of 10
http://www.actaneurocomms.org/content/1/1/5316. Landis JR, Koch GG: The measurement of observer agreement for
categorical data. Biometrics 1977, 33:159–174.
17. Al-Sarraj S, King A, Troakes C, et al: p62 positive, TDP-43 negative,
neuronal cytoplasmic and intranuclear inclusions in the cerebellum and
hippocampus define the pathology of C9orf72-linked FTLD and MND/
ALS. Acta Neuropathol 2011, 122:691–702.
18. Murray ME, Dejesus-Hernandez M, Rutherford NJ, et al: Clinical and
neuropathologic heterogeneity of c9FTD/ALS associated with
hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 2011,
122:673–690.
19. Rice CM, Gilkes CE, Teare E, et al: Brain biopsy in cryptogenic neurological
disease. Br J Neurosurg 2011, 25:614–620.
20. Hauw JJ, Duyckaerts C: Dementia, the fate of brain? Neuropathological
point of view. C R Biol 2002, 325:655–664.
21. Javedan SP, Tamargo RJ: Diagnostic yield of brain biopsy in
neurodegenerative disorders. Neurosurgery 1997, 41:823–828.
22. Dwork AJ, Liu D, Kaufman MA, Prohovnik I: Archival, formalin-fixed tissue:
its use in the study of Alzheimer's type changes. Clin Neuropathol 1998,
17:45–49.
23. Pikkarainen M, Martikainen P, Alafuzoff I: The effect of prolonged fixation
time on immunohistochemical staining of common neurodegenerative
disease markers. J Neuropathol Exp Neurol 2010, 69:40–52.
24. Furukawa Y, Iseki E, Hino H, et al: Ubiquitin and ubiquitin-related proteins
in the brains of patients with atypical Pick's disease without Pick bodies
and dementia with motor neuron disease. Neuropathology 2004,
24:306–314.
25. Kuusisto E, Kauppinen T, Alafuzoff I: Use of p62/SQSTM1 antibodies for
neuropathological diagnosis. Neuropathol Appl Neurobiol 2008, 34:169–180.
26. Kuusisto E, Parkkinen L, Alafuzoff I: Morphogenesis of Lewy bodies:
dissimilar incorporation of alpha-synuclein, ubiquitin, and p62.
J Neuropathol Exp Neurol 2003, 62:1241–1253.
27. Davidson YS, Raby S, Foulds PG, et al: TDP-43 pathological changes in
early onset familial and sporadic Alzheimer's disease, late onset
Alzheimer's disease and down's syndrome: association with age,
hippocampal sclerosis and clinical phenotype. Acta Neuropathol 2011,
122:703–713.
28. Parchi P, Castellani R, Capellari S, et al: Molecular basis of phenotypic
variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996,
39:767–778.
29. Parchi P, Giese A, Capellari S, et al: Classification of sporadic Creutzfeldt-
Jakob disease based on molecular and phenotypic analysis of 300
subjects. Ann Neurol 1999, 46:224–233.
30. Lashley T, Rohrer JD, Bandopadhyay R, et al: A comparative clinical,
pathological, biochemical and genetic study of fused in sarcoma
proteinopathies. Brain 2011, 134:2548–2564.
31. Neumann M, Rademakers R, Roeber S, et al: A new subtype of
frontotemporal lobar degeneration with FUS pathology. Brain 2009,
132:2922–2931.
32. Wagner JA: Biomarkers: principles, policies, and practice. Clin Pharmacol
Ther 2009, 86:3–7.
doi:10.1186/2051-5960-1-53
Cite this article as: King et al.: Simulated surgical-type cerebral biopsies
from post-mortem brains allows accurate neuropathological diagnoses
in the majority of neurodegenerative disease groups. Acta
Neuropathologica Communications 2013 1:53.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
